Published in BMJ Clin Evid on January 09, 2009
CLEAR Study: Clinical Experience Acquired With Raptiva Study | NCT00256139
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol (2003) 3.28
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol (2005) 3.18
Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol (1977) 2.53
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 2.50
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12
Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95
A systematic review of treatments for severe psoriasis. Health Technol Assess (2000) 1.93
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol (2003) 1.91
A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol (2003) 1.77
Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol (2003) 1.77
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol (2005) 1.72
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat (2007) 1.60
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol (1996) 1.58
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol (2006) 1.58
Saline spa water or combined water and UV-B for psoriasis vs conventional UV-B: lessons from the Salies de Béarn randomized study. Arch Dermatol (2001) 1.53
A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J Invest Dermatol (2007) 1.52
Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol (1997) 1.51
A controlled study of ultraviolet A sunbed treatment of psoriasis. Br J Dermatol (2000) 1.48
Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med (1993) 1.47
Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum (1984) 1.46
A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis. Clin Exp Dermatol (2000) 1.46
Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatolog Treat (2001) 1.45
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2004) 1.43
Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol (2000) 1.41
Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol (1995) 1.40
Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med (1991) 1.38
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol (2002) 1.33
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol (2005) 1.32
The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer (1994) 1.17
Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ (2000) 1.11
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol (2006) 1.10
Pulmonary function in patients receiving long-term low-dose methotrexate. Chest (1996) 1.06
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol (2005) 1.03
Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol (1989) 1.03
Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol (2003) 0.98
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol (2003) 0.98
A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol (1999) 0.98
Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol (2004) 0.96
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther (2005) 0.96
UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol (2005) 0.96
Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol (2002) 0.94
Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol (1999) 0.93
Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol (2006) 0.92
Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol (2005) 0.91
Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology (2003) 0.91
Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol (1998) 0.91
Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol (1994) 0.89
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol (2006) 0.89
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol (2005) 0.89
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol (2006) 0.89
Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol (2005) 0.88
A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology (2002) 0.88
Effects of psychologic intervention on psoriasis: a preliminary report. J Am Acad Dermatol (1996) 0.88
An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol (2007) 0.87
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol (2003) 0.86
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol (2006) 0.86
Supervised four-week heliotherapy alleviates the long-term course of psoriasis. Acta Derm Venereol (1993) 0.86
Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol (1997) 0.85
Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol (2005) 0.83
The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg (2005) 0.83
Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol (2004) 0.83
Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol (1997) 0.83
Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol (1998) 0.83
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol (1998) 0.82
A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol (2002) 0.82
Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica (1991) 0.81
Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica (1983) 0.81
The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol (1995) 0.81
The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol (2003) 0.81
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol (2002) 0.81
How do the biologics fit into the current DMARD armamentarium? J Rheumatol Suppl (2001) 0.81
Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology (2000) 0.80
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther (2000) 0.80
A controlled trial of acupuncture in psoriasis: no convincing effect. Acta Derm Venereol (1997) 0.80
Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg (2001) 0.80
Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology (2002) 0.79
Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. Arch Dermatol (1999) 0.78
Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol (1999) 0.78
A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis. Br J Rheumatol (1994) 0.77
Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol (2002) 0.77
Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base. A single-blind controlled study. Acta Derm Venereol (1990) 0.77
Effect of dietary supplementation with n-3 fatty acids on clinical manifestations of psoriasis. Br J Dermatol (1988) 0.77
Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol (1999) 0.76
The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a prospective randomized clinical trial. Int J Dermatol (2006) 0.76
An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol (2006) 0.76
The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol (1998) 0.76
The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol (2004) 0.76
Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol (2006) 0.76
Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol (2000) 0.76
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol (2005) 0.76
Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther (2008) 1.90
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol (2007) 1.59
Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg (2010) 1.33
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges (2012) 1.25
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol (2006) 1.06
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges (2011) 1.04
A validated lip fullness grading scale. Dermatol Surg (2008) 1.01
The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study. Dermatol Surg (2009) 1.00
Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of severe nasolabial lines - 6-month interim results of a randomized, evaluator-blinded, intra-individual comparison study. J Cosmet Dermatol (2011) 0.99
Disclosure of potential conflicts of interest in dermatological guidelines in Germany - an analysis - status quo and quo vadis. J Dtsch Dermatol Ges (2011) 0.99
A validated grading scale for forehead lines. Dermatol Surg (2008) 0.99
Risk profiles of different injectable fillers: results from the Injectable Filler Safety Study (IFS Study). Dermatol Surg (2007) 0.98
Validated assessment scales for the lower face. Dermatol Surg (2012) 0.97
[S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges (2011) 0.96
A validated hand grading scale. Dermatol Surg (2008) 0.96
A validated grading scale for marionette lines. Dermatol Surg (2008) 0.95
Validated assessment scales for the upper face. Dermatol Surg (2012) 0.95
A validated grading scale for crow's feet. Dermatol Surg (2008) 0.94
Anatomic guidelines for augmentation of the cheek and infraorbital hollow. Dermatol Surg (2012) 0.94
Facial Soft-Tissue Fillers conference: Assessing the State of the Science. J Am Acad Dermatol (2011) 0.92
Reproducibility of two four-point clinical severity scores for lateral canthal lines (crow's feet). Dermatol Surg (2006) 0.88
Risk of severe adverse reactions to an injectable filler based on a fixed combination of hydroxyethylmethacrylate and ethylmethacrylate with hyaluronic acid. Dermatol Surg (2009) 0.87
Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges (2007) 0.86
[S3-Guidelines for the therapy of psoriasis vulgaris]. J Dtsch Dermatol Ges (2006) 0.85
Validated assessment scales for the mid face. Dermatol Surg (2012) 0.84
Decrease of reported adverse events to injectable polylactic acid after recommending an increased dilution: 8-year results from the Injectable Filler Safety study. J Cosmet Dermatol (2009) 0.84
A validated brow positioning grading scale. Dermatol Surg (2008) 0.83
In vivo determination of skin surface topography using an optical 3D device. Skin Res Technol (2004) 0.83
[S2k-guideline for therapy of acne]. J Dtsch Dermatol Ges (2010) 0.83
[Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis]. J Dtsch Dermatol Ges (2004) 0.82
Confirming the hypothesis at any cost? Dtsch Arztebl Int (2014) 0.82
Peripheral blood T-cell clonality in mycosis fungoides and nonlymphoma controls. Diagn Mol Pathol (2003) 0.81
Chronic plaque psoriasis. Clin Evid (2004) 0.80
Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol (2010) 0.80
A 12-Month Follow-up, Randomized Comparison of Effectiveness and Safety of Two Hyaluronic Acid Fillers for Treatment of Severe Nasolabial Folds. Dermatol Surg (2017) 0.80
Perioral rejuvenation with a range of customized hyaluronic acid fillers: efficacy and safety over six months with a specific focus on the lips. J Drugs Dermatol (2012) 0.79
E-learning in the dermatological education at the Charité: evaluation of the last three years. J Dtsch Dermatol Ges (2008) 0.79
[S3-guidelines for the treatment of psoriasis vulgaris--methods report]. J Dtsch Dermatol Ges (2011) 0.78
Efficacy and durability of two hyaluronic acid-based fillers in the correction of nasolabial folds: results of a prospective, randomized, double-blind, actively controlled clinical pilot study. Dermatol Surg (2011) 0.78
Sustained efficacy and high patient satisfaction after cheek enhancement with a new hyaluronic acid dermal filler. J Drugs Dermatol (2012) 0.77
The current state of treatment of adverse reactions to injectable fillers. Dermatol Surg (2010) 0.77
Consensus Recommendations for Optimal Augmentation of the Asian Face with Hyaluronic Acid and Calcium Hydroxylapatite Fillers. Plast Reconstr Surg (2015) 0.77
Anatomy of the cheek: implications for soft tissue augmentation. Dermatol Surg (2012) 0.76
Chronic plaque psoriasis. Clin Evid (2002) 0.76
Chronic plaque psoriasis. Clin Evid (2005) 0.76
Translating psoriasis treatment guidelines into clinical practice - the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract (2008) 0.76
[Epidemiology of acne]. J Dtsch Dermatol Ges (2010) 0.75
Head-to-head studies of botulinum toxin A in aesthetic medicine: which evidence is good enough? J Am Acad Dermatol (2007) 0.75
Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices. Dermatol Surg (2016) 0.75
Facial Soft-Tissue Fillers: Assessing the State of the Science conference---Proceedings report. J Am Acad Dermatol (2011) 0.75
[Evidence and eminence]. J Dtsch Dermatol Ges (2008) 0.75
Hand augmentation with stabilized hyaluronic acid (Macrolane VRF20 and Restylane Vital, Restylane Vital Light). J Dtsch Dermatol Ges (2009) 0.75
Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study. Dermatol Surg (2015) 0.75
[Development of the evidence-based guidelines for psoriasis--a project of the German Dermatological Society (DDG)]. J Dtsch Dermatol Ges (2005) 0.75
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". J Dtsch Dermatol Ges (2010) 0.75
[Esthetic dermatology for students: good acceptability of a new voluntary seminar]. J Dtsch Dermatol Ges (2010) 0.75
[Online bedside teaching: multimedia, interactive and case-based teaching scenarios in dermatology]. J Dtsch Dermatol Ges (2004) 0.75
Emervel®: full-face rejuvenation with a range of customized hyaluronic acid fillers. J Drugs Dermatol (2012) 0.75
Chronic plaque psoriasis. Clin Evid (2002) 0.75
Aesthetic correction of the upper lip in a patient with mandibular prognathia with a novel long-lasting collagen filler: a case report. Dermatol Surg (2007) 0.75
European expert recommendations on the use of injectable poly-L-lactic acid for facial rejuvenation. J Drugs Dermatol (2014) 0.75
[Efficacy, side effects and patient satisfaction with wrist conduction block anaesthesia prior to the treatment of palmar hyperhidrosis with botulinum toxin type A]. J Dtsch Dermatol Ges (2003) 0.75
Three years after the publication of the German (S3) evidence based psoriasis guidelines--was it worth the effort? J Dtsch Dermatol Ges (2009) 0.75
Facial soft-tissue fillers conference: assessing the state of the science. Plast Reconstr Surg (2011) 0.75
Validated assessment scale for neck volume. Dermatol Surg (2012) 0.75
[Austrian men are quicker than women]. J Dtsch Dermatol Ges (2009) 0.75
Assessment of publications using methods of evidence-based medicine: an introduction using a dermatological clinical study. J Dtsch Dermatol Ges (2007) 0.75
Acne--what counts! J Eur Acad Dermatol Venereol (2013) 0.75
[Conflicts of interest: an introduction to a new focus point]. J Dtsch Dermatol Ges (2011) 0.75
A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus. J Drugs Dermatol (2008) 0.75
[Continuing medical education in Aesthetic Medicine: hands--on course on the usage of hyaluronic acids of different particle size on anatomic preparations]. J Dtsch Dermatol Ges (2007) 0.75
First Consensus on Primary Prevention and Early Intervention in Aesthetic Medicine. J Drugs Dermatol (2017) 0.75
[Continuing medical education in aesthetic medicine: hands-on course with anatomic preparations for hand augmentation with injectable hyaluronic acids]. J Dtsch Dermatol Ges (2008) 0.75
[Using new media for online consensus conferences and open external review of guidelines - results of two pilot studies]. Z Evid Fortbild Qual Gesundhwes (2011) 0.75
Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis (2005) 0.75
Validated assessment scale for platysmal bands. Dermatol Surg (2013) 0.75
Consensus Recommendations for Combined Aesthetic Interventions Using Botulinum Toxin, Fillers, and Microfocused Ultrasound in the Neck, Décolletage, Hands, and Other Areas of the Body. Dermatol Surg (2016) 0.75
Communication Concepts for Prevention and Early Intervention in Aesthetic Medicine: Consensus and Literature Review. J Drugs Dermatol (2017) 0.75
Chronic plaque psoriasis. Clin Evid (2006) 0.75
Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment. J Drugs Dermatol (2008) 0.75